Librela Facts

We are aware of the very vibrant communities of pet owners that share their stories and pictures of their pets online. Some of them even chose to share their success stories with us.

We also understand that when your pet becomes sick, it is natural to search for answers. While social media can be a valuable source for pet owners to gather information, anecdotes and advice, community experiences such as those provided by these social media groups and forums are not a substitute for accurate answers from veterinary experts. 

If you have questions about medications for your pet and/or are concerned that your pet may be experiencing an adverse reaction to any medication, it is essential that you speak with your veterinarian. They know your pet and their medical history best, and an accurate diagnosis is essential to receiving the proper care.

Pet owners can also connect directly with our team of veterinarians and veterinary technicians who can help answer your questions. They can be contacted here:‑support/vmips/pet‑owner‑contact

Ask Questions About Our Products

Please refer to the full Prescribing Information for approved product labeling and Important Safety Information.

Contact our Zoetis Veterinary Medical Information Product Support (VMIPS) at 1‑888‑963‑8471

You may also contact our veterinary team using this form:

IMPORTANT SAFETY INFORMATION: See full Prescribing Information. For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis.

  1. Global pharmacovigilance data on file.
  2. Michels GM, Honsberger NA, Walters RR, Tena JKS, Cleaver DM. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Veterinary Anaesthesia and Analgesia 2023; 50(5): 446-458. (
  3. Corral MJ, Moyaert H, Fernandes T, Escalada M, Kira S Tena J, Walters RR, Stegemann MR. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Veterinary Anaesthesia and Analgesia 2021;48(6):943-955. (doi: 10.1016/j.vaa.2021.08.001).
  4. Brown DC, Boston RC, Coyne JC, Farrar JT. Development and psychometric testing of an instrument designed to measure chronic pain in dogs with osteoarthritis. Am J Vet Res. 2007;68(6):631-637. doi:10.2460/ajvr.68.6.631
  5. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the Canine Brief Pain Inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233(8):1278-1283. doi:10.2460/ javma.233.8.1278
  6. Reid J, Bartram D, Thompson J, Scales-Theobald E, Gildea E. Measuring improvement in quality of life of dogs with osteoarthritis (OA) treated with bedinvetmab (Librela®) using an app-based, validated, owner-reported, health-related quality of life (HRQL) outcome measure (VetMetrica™). Frontiers in Veterinary Science 2024 (under review)
  7. Librela (bedinvetmab injection). Prescribing information. NADA 141-562. Zoetis Inc; March 2023.